A Phase I, dose‐finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors,

Olaparib (AZD2281) is an orally active Poly(ADP‐ribose) polymerase (PARP) inhibitor with favorable antitumor activity in advanced ovarian and breast cancers with BRCA1/2 mutations in Western (USA and European) studies. This Phase I dose‐finding study evaluated the tolerability, pharmacokinetics, PAR...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Sci
Main Authors: Yamamoto, Noboru, Nokihara, Hiroshi, Yamada, Yasuhide, Goto, Yasushi, Tanioka, Maki, Shibata, Takashi, Yamada, Kazuhiko, Asahina, Hajime, Kawata, Toshio, Shi, Xiaojin, Tamura, Tomohide
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 2012
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7713608/
https://ncbi.nlm.nih.gov/pubmed/22145984
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.2011.02179.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados